Loading…

Arvinas, Inc.ARVNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum weak 23
Mkt cap
$443M
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$7.29M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 14.0%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
1 Mar 2027
Close · USD$6.76
1D-0.8%
1W-2.1%
1M-11.7%
3M-25.0%
6M-25.7%
YTD-43.0%
1Y-38.7%
ATR %6.0%
Beta1.31
52w lowhigh53.4% off high

What Arvinas does

Employees: 246

Arvinas at a glance

Size Arvinas (ARVN) is a United States Health Care company (Biotechnology) with a market value of $443M, the 2761st largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.76 on 18 Nov 2026.

Performance Over six months the shares fell 25.7%, against -9.3% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 19 in its peer set.

Growth Revenue fell 11.8% over the last twelve months (peer median +4.8%); the operating margin is -10.1% (peer median -4.5%).

Backlog Backlog (remaining performance obligations) was $190M at 31 Mar 2026, down 27% on a year earlier — 2.1 years of trailing revenue. Backlog detail →

Short interest Short interest is 8.8% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 91ARVN 74
Six months, rebased to 100: Arvinas against the median of its 20 peers (local-currency closes).

Arvinas financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$275M$263M$263M$78.5M$131M
Revenue growth—0%+236%-40%—
Gross profit$262M$257M$257M$71.8M$123M
EBITDA-$23.2M-$110M-$200M-$395M-$255M
Net income-$9.50M-$80.8M-$199M-$367M-$282M
Free cash flow-$160M-$276M-$261M-$351M-$280M
Capital expenditure$1.50M$1.90M$1.80M$2.90M$6.80M
Total debt$7.60M$9.10M$9.90M$3.40M$5.50M

Quarterly statements and history in the cockpit →

Arvinas competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-40%-20%0%+20%6589IRLA0007106037391789115180041960STTKPRTA250967126547DMAC688317476830CADLFENCARVN6-month return →1-month return →
Up and to the right = strong over both horizons. Arvinas is the large dot.

Arvinas competitors and peer comparison

How Arvinas compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Arvinas against its 20 peers (data as of 18 Nov 2026)
MeasureARVNPeer medianRank in peer set
1-month return-11.7%-11.6%11th highest of 21
6-month return-25.7%-9.3%5th lowest of 19
Distance from 52-week high-53.4%-38.9%6th lowest of 21
Revenue growth (TTM)-11.8%+4.8%4th lowest of 16
Operating margin-10.1%-4.5%8th lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%

Arvinas backlog

Arvinas reported $190M of remaining performance obligations at 31 Mar 2026, down 27% from a year earlier and down 8% from the previous quarter. That is 2.1 years of trailing revenue already under contract. Book-to-bill last quarter: 0.00.

Questions

Which companies are Arvinas's closest peers?
The cockpit's peer set: EirGenix (6589.TW), IRulya Therapeutics (IRLA), Berry Genomics (000710.SZ), Qingdao Vland Biotech (603739.SS), Scinopharm Taiwan (1789.TW), Qurient (115180.KS), Komipharm International (041960.KS), Shattuck Labs (STTK).
How has Arvinas stock performed?
Over six months to 18 Nov 2026 the shares returned -25.7% against -9.3% for the median peer; over one year -38.7%.
What is Arvinas's backlog?
Arvinas's remaining performance obligations (contracted revenue not yet recognised) were $190M at 31 Mar 2026, -27% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.